The company manufactures and exports generic pharmaceutical formulations, specializing in sterile injectables, tablets, and capsules for both government tenders and private hospital chains.
The company lacks a durable moat as evidenced by low net margins (4.4%) and a heavy reliance on competitive government tenders. While they are moving into complex generics and branded domestic sales, these segments have not yet translated into superior or stable returns on capital.
Management has aggressively reinvested in new subsidiaries like Innoxel and Varenyam Bio to enter regulated markets. While this has expanded the asset base, it has led to significant consolidated losses and negative interest coverage in the short term.
The aggressive expansion into regulated markets through subsidiaries like Innoxel and Varenyam Bio became a permanent drain on capital rather than a growth engine. The consolidated losses eventually overwhelmed the standalone profits, while the massive pile of aged receivables—already 40% overdue—proved uncollectible, leading to a liquidity crunch. The internal control weaknesses hinted at by the auditor's resignation and bank reporting discrepancies materialized into a full-scale accounting restatement, destroying investor trust and leaving the company unable to service its 180-crore debt load.
RichFakir rates Bharat Parenterals Ltd's business quality as poor — 30/100 on our quality score (profitability, growth, balance-sheet strength and capital allocation). We assess its competitive moat as none.
On our model, Bharat Parenterals Ltd is trading far above our estimate of fair value (expensive on our lens); we rate its price expensive. This is an educational estimate from public filings, not a recommendation.
RichFakir's educational verdict on Bharat Parenterals Ltd is: Not rated. A poor business at an expensive price — it does not make our shortlist right now.
RichFakir's educational estimate of Bharat Parenterals Ltd's fair value is about ₹75 per share, derived from public filings. It's our estimate for research — not a price target or a recommendation to buy or sell.
View the full live analysis →